Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients

Journal of Hematology & Oncology

Joseph D. Khoury²  L. Jeffrey Medeiros²  Roberto N. Miranda²  C. Cameron Yin²  Shimin Hu²  Guilin Tang²  Siok-Bian Ng¹  Zhuang Zuo²  Tariq N. Aladily³  Khaled Alayed⁴  Sanam Loghavi² 

[1] Department of Pathology, National University of Singapore and Cancer Science Institute, Singapore, Singapore;Department of Hematopathology, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, MS-072, Houston 77030, TX, USA;Department of Pathology and Laboratory Medicine, The University of Jordan, Amman, Jordan;Department of Pathology, King Saud University, Riyadh, Saudi Arabia

关键词: MYC;    Immunocompetent;    Immunodeficiency;    HIV;    EBV;    Plasmablastic lymphoma;   

Others  :  1217371
DOI  :  10.1186/s13045-015-0163-z

 received in 2015-02-27, accepted in 2015-05-28,  发布年份 2015

【 摘 要 】

Background

Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid and plasmacytic differentiation that is commonly associated with immunodeficiency and an unfavorable prognosis. Clinicopathologic features have been largely derived from cases reports and small series with limited outcome analyses.

Patients and methods

The demographic, clinicopathologic features, and clinical outcomes of a cohort of 61 patients with PBL were reviewed and analyzed.

Results

Patients had a median age of 49 years (range 21–83 years) and most (49/61; 80 %) were men. Human immunodeficiency virus (HIV) status was available for 50 patients: 20 were HIV-positive and 30 HIV-negative. Twenty-three patients were immunocompetent. Abdominal/gastrointestinal complaints were the most common presenting symptoms, reported in 14 of 47 (30 %) of patients. At presentation, 24 of 43 (56 %) patients had stage III or IV disease. Epstein-Barr virus (EBV) was detected in 40 of 57 (70 %) cases. MYC rearrangement was identified in 10/15 (67 %) cases assessed, and MYC overexpression was seen in all cases assessed regardless of MYC rearrangement status. HIV-positive patients were significantly younger than those who were HIV-negative (median 42 vs. 58 years; p = 0.006). HIV-positive patients were also significantly more likely to have EBV-positive disease compared with HIV-negative patients (19/19, 100 % vs. 15/29, 52 %; p = 0.002). Patients who received CHOP chemotherapy tended to have better overall survival (OS) compared with those who received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) (p = 0.078). HIV status had no impact on OS. Patients with EBV-positive PBL had a better event-free survival (EFS) (p = 0.047) but not OS (p = 0.306). Notably, OS was adversely impacted by age ≥50 years (p = 0.013), stage III or IV disease (p = <0.001), and lymph node involvement (p = 0.008).

Conclusions

The most significant prognostic parameters in patients with PBL are age, stage, and, to a lesser extent, EBV status. In this study, two-thirds of PBL cases assessed were associated with MYC rearrangement and all showed MYC overexpression.

【 授权许可】

   
2015 Loghavi et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Stein H, Harris NL, Campo E et al.. Plasmablastic lymphoma. In: WHO classification of tumours of haematopoietic and lymphoid tissues. Swerdlow SH, Campo E, Harris NL, editors. IARC, Lyon; 2008: p.256-7.
• [2]Fink K. Origin and function of circulating plasmablasts during acute viral infections. Front Immunol. 2012; 3:78.
• [3]Covens K, Verbinnen B, Geukens N et al.. Characterization of proposed human B-1 cells reveals pre-plasmablast phenotype. Blood. 2013; 121:5176-83.
• [4]Miranda RN, Khoury JD, Medeiros LJ. Plasmablastic Lymphoma. In: Atlas of Lymph Node Pathology. Springer, New York; 2014: p.265-8.
• [5]Morscio J, Dierickx D, Nijs J et al.. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol. 2014; 38:875-86.
• [6]Horn H, Staiger AM, Vohringer M et al.. Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations. Am J Surg Pathol. 2015; 39:61-6.
• [7]Castillo JJ. Plasmablastic lymphoma: are more intensive regimens needed? Leuk Res. 2011; 35:1547-8.
• [8]Chang CC, Zhou X, Taylor JJ et al.. Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol. 2009; 2:47. BioMed Central Full Text
• [9]Vega F, Chang CC, Medeiros LJ et al.. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005; 18:806-15.
• [10]Banks PM, Keller RH, Li CY, White WL. Malignant lymphoma of plasmablastic identity. A neoplasm with both “immunoblastic” and plasma cellular features. Am J Med. 1978; 64:906-9.
• [11]Delecluse HJ, Anagnostopoulos I, Dallenbach F et al.. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997; 89:1413-20.
• [12]Castillo JJ, Reagan JL. Plasmablastic lymphoma: a systematic review. Sci World J. 2011; 11:687-96.
• [13]Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015; 125(15):2323-30.
• [14]Hsi ED, Lorsbach RB, Fend F, Dogan A. Plasmablastic lymphoma and related disorders. Am J Clin Pathol. 2011; 136:183-94.
• [15]Cattaneo C, Re A, Ungari M, et al. Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center’s experience. Leuk Lymphoma. 2014;1–3
• [16]Zelenetz AD, Abramson JS, Advani RH et al.. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas. J Natl Compr Canc Netw. 2010; 8:288-334.
• [17]Saba NS, Dang D, Saba J et al.. Bortezomib in plasmablastic lymphoma: a case report and review of the literature. Onkologie. 2013; 36:287-91.
• [18]Castillo JJ, Winer ES, Stachurski D et al.. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist. 2010; 15:293-9.
• [19]Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008; 83:804-9.
• [20]Castillo JJ, Furman M, Beltran BE et al.. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012; 118:5270-7.
• [21]Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM et al.. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica. 2010; 95:1342-9.
• [22]Colomo L, Loong F, Rives S et al.. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol. 2004; 28:736-47.
• [23]Teruya-Feldstein J. Diffuse large B-cell lymphomas with plasmablastic differentiation. Curr Oncol Rep. 2005; 7:357-63.
• [24]Carbone A, Gloghini A, Vaccher E et al.. KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype. J Clin Pathol. 2005; 58:1039-45.
• [25]Pan ZG, Zhang QY, Lu ZB et al.. Extracavitary KSHV-associated large B-cell lymphoma: a distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases. Am J Surg Pathol. 2012; 36:1129-40.
• [26]Carbone A, Volpi CC, Caccia D et al.. Extracavitary KSHV-positive solid lymphoma: a large B-cell lymphoma within the spectrum of primary effusion lymphoma. Am J Surg Pathol. 2013; 37:1460-1.
• [27]Swerdlow SH, Webber SA, Chadburn A, Ferry JA et al.. Post-transplant lymphoproliferative disorders. In: WHO classification of tumours of haematopoietic and lymphoid tissues. Swerdlow SH, Campo E, Harris NL, editors. IARC, Lyon; 2008: p.343-9.
• [28]Loghavi S, Khoury JD, Medeiros JL. Epstein-Barr Virus-positive Plasmacytoma in Immunocompetent Patients. Histopathology. 2015: Jan 2. doi:10.1111/his.12640. [Epub ahead of print].
• [29]Khoury JD, Sen F, Abruzzo LV et al.. Cytogenetic findings in blastoid mantle cell lymphoma. Hum Pathol. 2003; 34:1022-9.
• [30]Tang G, Zhang L, Fu B et al.. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol. 2014; 89(8):813-8.
• [31]Shaffer LG SM, Campbell LJ. An international system for human cytogenetic nomenclature. Basel, Switzerland; 2009.
• [32]Freeman SS, Allen SW, Ganti R et al.. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer. 2008; 113(6):1453-61.